泰国5-11岁儿童中分数剂量、异源新冠疫苗基础免疫程序联合BNT162b2加强针的免疫原性与反应原性:多中心、前瞻性、双盲、随机对照试验
这项多中心、前瞻性、双盲、随机对照试验在553名5-11岁泰国儿童中比较了CoronaVac与BNT162b2(标准10μg或半剂5μg)异源基础免疫程序及后续BNT162b2加强针的免疫原性与安全性。结果显示所有程序均诱导相似稳健的中和抗体,半剂BNT162b2作为第二剂诱导的中和抗体滴度显著低于相应全剂方案,加强针后针对BA.1的中和抗体滴度较第二剂升高5.69-11.51倍,不良事件均为轻中度且2-3天内完全缓解。作者认为标准与分数剂量异源CoronaVac-BNT162b2程序诱导的体液免疫相似或高于同源BNT162b2,可作为儿童替代疫苗方案。
要点
- 第二剂后两周所有组抗原始Wuhan株中和抗体均稳健,组1滴度最高(737.60,95%CI 654.80-830.88)。
- 半剂BNT162b2第二剂诱导的中和抗体滴度显著低于相应全剂方案(组1 vs 2 p=0.03;组3 vs 4 p<0.001)。
- 加强针针对BA.1的中和抗体滴度较第二剂升高5.69-11.51倍,不良事件均轻中度且2-3天完全缓解。
核心结论
- 标准与分数剂量异源CoronaVac-BNT162b2程序诱导的体液免疫相似或高于同源BNT162b2,可作为儿童替代疫苗方案。
- 这些发现对同时使用两种疫苗的环境高度相关。
研究设计与样本
- 多中心、前瞻性、双盲、随机对照试验,将参与者按1:1:1:1分为四组。
- 553名5-11岁泰国儿童入组,50%为男性,中位(四分位距)年龄8.65(7.00,10.00)岁,91%体重别身高正常。
- 各组第二剂分别为CoronaVac/10μg-BNT162b2(组1)、CoronaVac/5μg-BNT162b2(组2)、10μg-BNT162b2/10μg-BNT162b2(组3)、10μg-BNT162b2/5μg-BNT162b2(组4)。
- 每组部分参与者在第二剂后16周接受10μg-BNT162b2加强针(第三剂)。
- 评估体液与细胞免疫原性,不良事件通过数字化自我报告。
主要发现
- 第二剂后两周抗原始Wuhan株中和抗体滴度组1为737.60(95%CI 654.80-830.88),组3为630.42(95%CI 555.50-715.45),组2为593.98(95%CI 506.02-697.23),组4为451.79(95%CI 388.62-525.23)。
- 针对BA.1和BA.5的血清转化率分别为56.01%和49.68%。
- 半剂BNT162b2第二剂诱导的中和抗体滴度显著低于相应全剂方案(组1 vs 2 p=0.03;组3 vs 4 p<0.001)。
- 77.71%参与者在第二剂后两周产生SARS-CoV-2原始株刺突蛋白特异性T细胞反应,各组间相似。
- 加强针针对BA.1的中和抗体滴度较第二剂升高5.69-11.51倍;不良事件各组相似,均为轻中度,2-3天后完全缓解。
关键数值与推荐
- 第二剂后两周中和抗体滴度:组1 737.60(95%CI 654.80-830.88),组3 630.42(95%CI 555.50-715.45),组2 593.98(95%CI 506.02-697.23),组4 451.79(95%CI 388.62-525.23)。
- 半剂与全剂第二剂比较:组1 vs 2 p=0.03;组3 vs 4 p<0.001。
- 针对BA.1和BA.5的血清转化率分别为56.01%和49.68%。
- 77.71%参与者产生刺突蛋白特异性T细胞反应。
- 加强针针对BA.1的中和抗体滴度较第二剂升高5.69-11.51倍。
临床怎么用
- 作者认为标准与分数剂量异源CoronaVac-BNT162b2程序可作为儿童替代疫苗方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate immunogenicity and safety of heterologous COVID-19 primary vaccination regimens of CoronaVac with fractional and standard BNT162b2 dosages in 5-11-year-old Thai children. METHODS: This prospective, multicenter, double-blind, randomized control trial divided participants 1:1:1:1 to receive a second dose of either standard (10-μg) or half-dose (5-μg) BNT162b2 vaccines as follows: CoronaVac/10-μg-BNT162b2 (Group 1), CoronaVac/5-μg-BNT162b2 (Group 2), 10-μg-BNT162b2/10-μg-BNT162b2 (Group 3), or 10-μg-BNT162b2/5-μg-BNT162b2 (Group 4). A subset of participants from each arm received 10-μg-BNT162b2 booster (third) doses 16 weeks after their second vaccination. Humoral and cellular immunogenicity were assessed and adverse events (AEs) digitally self-reported. RESULTS: Of 553 enrolled participants, 50 % were male, the median (interquartile range) age was 8.65 (7.00, 10.00) years, and a majority (91 %) had normal weight-for-height. All participants exhibited similarly robust neutralizing antibodies (NAb) against the ancestral Wuhan strain two weeks after the second vaccination, with titers highest in Group 1 (737.60, 95% CI [654.80, 830.88]), followed by Groups 3 (630.42, 95% CI [555.50, 715.45]), 2 (593.98, 95% CI [506.02, 697.23]), and 4 (451.79, 95% CI [388.62, 525.23]), as well as 56.01 % and 49.68 % seroconversion for BA.1 and BA.5, respectively. Half-dose BNT162b2 as a second dose induced significantly lower NAb titers compared to their respective full-dose regimens (p = 0.03 for Groups 1 vs 2 and p < 0.001 for Groups 3 vs 4). 77.71 % of participants developed SARS-CoV-2 ancestral spike protein-specific T-cell responses two weeks after the second vaccination. This was similar across arms. Booster doses generated NAb titers 5.69-11.51-folds higher than the second vaccination against BA.1. AEs were similar across arms, all mild or moderate, and fully resolved 2-3 days thereafter. CONCLUSION: Standard and fractional heterologous regimens of CoronaVac-BNT162b2 induced similar or higher humoral immunity than homologous BNT162b2 and represent alternative vaccine regimens for children. These findings are highly relevant in settings concurrently using both vaccines.
引用
- Wittawatmongkol O, Bunjoungmanee P, Kosalaraksa P, et al. Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial. Vaccine. 2023. PMID: 37586956. doi:10.1016/j.vaccine.2023.08.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。